Cannabinoids for drug-resistant epilepsy in adults and children
Part of Brain & nervous system, Mental health clinical trials.
This trial tests if cannabinoids can help people who still have seizures despite trying two or more standard seizure medications. It aims to reduce seizure frequency in those with drug-resistant epilepsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 24 months and 55 years old
- You have tried at least 2 seizure medications without success
- You have 4 or more clearly recognizable seizures each month
- You agree not to drive or use recreational cannabis during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether a low dose of IV ketamine can reduce seizures in adults with drug-resistant epilepsy. It may help people whose seizures continue despite trying at least two appropriate seizure medicines.
This trial tests if transcranial magnetic stimulation (TMS, a non-invasive brain stimulation) targeting the cerebellum can safely reduce seizures over time in people with drug-resistant epilepsy. It aims to find a new treatment option for those whose seizures aren't controlled by medication.
This study looks at how well the ketogenic diet (a high-fat, low-carb diet) works for children with epilepsy that doesn't improve with standard medicines. It uses a special product called KetoCal to help maintain the diet and tracks results in real life.
This trial tests if adding cannabidiol (CBD) to your child's current seizure medicines can reduce seizures. It uses a personalized approach to see if CBD works for each child.
This trial tests a new cannabidiol (CBD) liquid medicine for people with focal epilepsy (seizures that start in one part of the brain). It looks at whether the medication can help reduce seizures when added to your current seizure medications.
This study tests a new CBD oil (CBD-OS) to see if it safely reduces seizures in people with developmental and epileptic encephalopathy (DEE), a condition where both development and seizure control are affected. Participants must already be on a stable antiseizure treatment.
Hear when a new Drug Resistant Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.